Clinical presentations and outcomes of COVID‐19 infection in sickle cell disease patients: Case series from Komfo Anokye teaching hospital, Ghana

Hardy, Yasmine; Amenuke, D.; Abukari, Yakubu; Oti‐Acheampong, Alexander; Hutton-Mensah, Kojo Awotwi; Amoah-Dankwah, James; Kontoh, Samuel Amoabeng; Danso, Kwabena A.; Berchie, Patrick; Otu‐Ansah, Caleb

doi:10.1002/ccr3.3719

Cited by 10 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… n/a 0 (0) Fronza et al [ 112 ] Italy 1 (0/1) 44 n/a BT (1) Patient recovered and was discharged after severe anemia and acute lung failure. n/a 0 (0) Hardy et al [ 113 ] Ghana 3 (0/3) 28 HbSS (1), HbSC (2) BT (2) One had severe COVID-19 pneumonia. Two had severe SCD crisis.…”

Section: Patients With Covid-19 and Sickle Cell Diseasementioning

confidence: 99%

Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature

et al. 2022

View full text Add to dashboard Cite

Section: Patients With Covid-19 and Sickle Cell Diseasementioning

confidence: 99%

Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature

et al. 2022

View full text Add to dashboard Cite

“…When compared with healthcare professionals infected with COVID-19 in the same age group, it is seen that patients have more comorbid conditions and develop more pneumonia as expected [23][24][25]. It was noteworthy that in addition to the comorbid state, one-third of the patients used ACE inhibitors for proteinuria or cardiac reasons.…”

Section: Discussionmentioning

confidence: 94%

Comparison of the clinical course of COVID-19 infection in sickle cell disease patients with healthcare professionals

et al. 2021

View full text Add to dashboard Cite

It is highly expected that COVID-19 infection will have devastating consequences in sickle cell disease (SCD) patients due to endothelial activation and decreased tissue and organ reserve as a result of microvascular ischemia and continuous inflammation. In this study, we aimed to compare the clinical course of COVID-19 in adult SCD patients under the organ injury mitigation and clinical care improvement program (BASCARE) with healthcare professionals without significant comorbid conditions. The study was planned as a retrospective, multicenter and cross-sectional study. Thirty-nine SCD patients, ages 18 to 64 years, and 121 healthcare professionals, ages 21 to 53, were included in the study. The data were collected from the Electronic Health Recording System of PRANA, where SCD patients under the BASCARE program had been registered. The data of other patients were collected from the Electronic Hospital Data Recording System and patient files. In the SCD group, the crude incidence of COVID-19 was 9%, while in healthcare professionals at the same period was 23%. Among the symptoms, besides fever, loss of smell and taste were more prominent in the SCD group than in healthcare professionals. There was a significant difference between the two groups in terms of development of pneumonia, hospitalization, and need for intubation (43 vs 5%, P < 0.00001; 26 vs 7%, P = 0.002; and 10 vs 1%, P = 0.002, respectively). Prophylactic low molecular weight heparin and salicylate were used more in the SCD group than in healthcare professionals group (41 vs 9% and 28 vs 1%; P < 0.0001 for both). The 3-month mortality rate was demonstrated as 5% in the SCD group, while 0 in the healthcare professionals group. One patient in the SCD group became continously dependent on respiratory support. The cause of death was acute chest syndrome in the first case, hepatic necrosis and multi-organ failure in the second case. In conclusion, these observations supported the expectation that the course of COVID-19 in SCD patients will get worse. The BASCARE program applied in SCD patients could not change the poor outcome.

show abstract

“…25 In a large population-based screening study in Bahrain, AbdulRahman et al 26 reported no difference in infection rate, clinical course, and viral clearance for SCD patients compared with those without SCD. Similarly, Arlet et al 20 reported no increased mortality or morbidity risk in a large cohort of patients in France, Chakravorty et al 27 reported a mild clinical course, and favorable outcomes in a cohort of patients in the United Kingdom, and Hardy et al 24 reported that SCD patients in Ghana did not seem to have a worse prognosis than patients without SCD.…”

Section: Discussionmentioning

confidence: 97%

SARS-CoV-2 Infection Presenting as Acute Chest Syndrome in a Child With Hemoglobin SD-Los Angeles Disease: A Case Report and Review of Literature

Calderwood

Sabir

Rao

et al. 2022

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Hemoglobin D-Los Angeles is a variant of hemoglobin that can polymerize in the deoxygenated state. When co-inherited with Hemoglobin S (HbSD-Los Angeles disease) a severe sickling syndrome similar to HbSS can result. Corona virus infectious disease 2019 (COVID-19) is caused by the severe acute respiratory syndromecorona virus-2. It has been associated with acute chest syndrome (ACS) in individuals with sickle cell disease (SCD), but this complication has not previously been reported in patients with HbSD-Los Angeles. Dexamethasone has been shown to improve outcomes in non-SCD patients with severe acute respiratory syndrome-corona virus-2 pneumonia or acute respiratory distress syndrome; however, its use in SCD patients with ACS is controversial due to a reported increased risk of complications including vaso-occlusive painful episodes. Herein, we reported a patient with HbSD-Los Angeles and COVID-19-associated ACS whom we treated with dexamethasone without transfusion. The patient experienced a rapid recovery without sequelae from steroid use.To further evaluate the use of steroids, we conducted a literature review focusing on the management of pediatric SCD patients with COVID-19-associated ACS. We identified a total of 39 pediatric patients with SCD and COVID-19, of whom 21 (54%) had ACS. Packed red blood cell transfusion (n = 11), exchange transfusion (n = 4), or a combination of exchange transfusion and packed red blood cell transfusion (n = 4) were the most frequently reported treatment, with hydroxychloroquine (n = 5), remdesivir (n = 1), and tocilizumab (n = 1) also being reported. Three patients were treated with dexamethasone. All patients recovered and no adverse outcomes from steroid use were reported. Even though transfusion is considered the standard of care for children with ACS and steroids are not routinely recommended, our experience suggested that COVID-19-associated ACS may be an important exception, especially for patients who refuse transfusion or are in resourcepoor nations where blood transfusions may not be readily available. Further studies are warranted to confirm these observations.

show abstract

Clinical presentations and outcomes of COVID‐19 infection in sickle cell disease patients: Case series from Komfo Anokye teaching hospital, Ghana

Abstract: Patients with sickle cell disease and COVID‐19 may not have a more dire outcome than the general population. Nevertheless, they may present with acute chest syndrome and other sickle cell crises which should be aggressively managed.

Cited by 10 publications

References 27 publications

Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature

Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature

Comparison of the clinical course of COVID-19 infection in sickle cell disease patients with healthcare professionals

SARS-CoV-2 Infection Presenting as Acute Chest Syndrome in a Child With Hemoglobin SD-Los Angeles Disease: A Case Report and Review of Literature

Contact Info

Product

Resources

About